American Society of Hirudotherapy

Proteinase inhibitors from the medicinal leech Hirudo medicinalis

Research article published in Biochemistry. Biokhimiia (2001)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Salivary PharmacologyDrug DevelopmentBaskova I, Zavalova L · Biochemistry. Biokhimiia, 2001

Abstract

The medicinal leech Hirudo medicinalis produces various types of proteinase inhibitors: bdellins (inhibitors of trypsin, plasmin, and acrosin), hirustasin (inhibitor of tissue kallikrein, trypsin, alpha-chymotrypsin, and granulocyte cathepsin G), tryptase inhibitor, eglins (inhibitors of alpha-chymotrypsin, subtilisin, and chymasin and the granulocyte proteinases elastase and cathepsin G), inhibitor of factor Xa, hirudin (thrombin inhibitor), inhibitor of carboxypeptidase, and inhibitor of complement component C1s. This review summarizes data on their primary and tertiary structures, action mechanisms, and biological activities.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsAntithrombin IIICarboxypeptidasesCarboxypeptidases AComplement Inactivator ProteinsHirudinsHumansInvertebrate HormonesLeechesOrganic ChemicalsProtease InhibitorsProteins

Summary

The medicinal leech Hirudo medicinalis produces various types of proteinase inhibitors: bdellins (inhibitors of trypsin, plasmin, and acrosin), hirustasin (inhibitor of tissue kallikrein, trypsin, alpha-chymotrypsin, and granulocyte cathepsin G), tryptase inhibitor, eglins (inhibitors of alpha-chymotrypsin, subtilisin, and chymasin and the granu...

Why This Matters for Hirudotherapy

Advances understanding of leech salivary bioactive compounds and their therapeutic potential.

Citation

Proteinase inhibitors from the medicinal leech Hirudo medicinalis.

Baskova I, Zavalova L · Biochemistry. Biokhimiia, 2001

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Proteinase inhibitors from the medicinal leech Hirudo medicinalis | ASH